Indian Journal of Nuclear Medicine

AUTHOR REPLY
Year
: 2019  |  Volume : 34  |  Issue : 4  |  Page : 354-

Author's reply


 

Correspondence Address:




How to cite this article:
. Author's reply.Indian J Nucl Med 2019;34:354-354


How to cite this URL:
. Author's reply. Indian J Nucl Med [serial online] 2019 [cited 2022 Oct 2 ];34:354-354
Available from: https://www.ijnm.in/text.asp?2019/34/4/354/267498


Full Text



Dear Reader,

We, the authors of “Unilateral Graves' disease: The lesser known,” thank you for your warm response and thought-provoking queries. Here, we are answering the questions to the best of our knowledge, after going through the given history and follow-up of the patients.

The mean duration of symptoms for these patients was 11.8 months (2–48 months). Three of the 15 patients were on antithyroid drugs before nuclear medicine consultation. One patient was on antithyroid drugs for 18 months and the other two patients were on for 1 year.Japan Thyroid Association uses the criteria as:

Clinical: Enlarged gland, symptoms of hyperthyroidism, and ophthalmopathy

Laboratory criteria: Elevated free T3 and T4 levels, serum thyroid-stimulating hormone levels <0.1 mIU/L, elevated uptake on the scan, and presence of antithyroid antibodies.

Of these criteria, antithyroid antibodies were not tested in any of the patients and all other laboratory criteria were fulfilled.

Only few patients had overt eye signs of Graves' disease. None of the patients underwent thyroidectomy. Either the patients are on antithyroid drugs or the patients underwent definitive radioactive iodine ablation. Remission after hemithyroidectomy in these patients has to be studied, and we do not have any data of the same.